Check out our latest podcast episode on Decarbonization. Watch now!

Sales & Support: +1 800 762 3361

Global Market Intelligence Constantly Updated Your Trusted Data Source for Industrial & Energy Market Intelligence

Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

While the quest for a COVID-19 vaccine garners the most attention in the news, there are obviously a plethora of other conditions that require treatment. Near the top of desired therapeutics are oncology (cancer) drugs. Biotech Gilead recently signed a $21 billion deal to purchase breast cancer drug developer Immunomedics Incorporated.

Subscribe Now!

(All Fields Required)

Fill Out Form To Subscribe +

First Name

Last Name

Email Address

Username

Password

Repeat Password

As a Member, you have access to:

Industry News Digest
IIR Podcast Episodes
Market Outlooks & Conference Events
Economic Indicators

View All Member Resources

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

For More Info!

Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

Login or Register for Instant Access

Subscribe Now!

Related Articles

As a Member, you have access to: